News Focus
News Focus
icon url

DewDiligence

12/31/13 2:29 PM

#187 RE: DewDiligence #178

ABBV/ENTA’s Phase-3 HCV Program in Japan: #msg-95444387.
icon url

DewDiligence

01/15/14 1:17 PM

#205 RE: DewDiligence #178

(Bullish) HCV GT1 stats from ABBV’s JPM webcast: #msg-95971165.
icon url

DewDiligence

04/12/14 4:16 PM

#364 RE: DewDiligence #178

Musings on US HCV pricing: #msg-100491031.
icon url

DewDiligence

06/17/14 5:02 PM

#445 RE: DewDiligence #178

Notes from today’s WF webcast: #msg-103400913.
icon url

DewDiligence

06/18/14 4:01 PM

#446 RE: DewDiligence #178

New all-time intraday ($44.48) and closing ($44.19) highs.
icon url

steveporsche

10/01/14 9:29 AM

#630 RE: DewDiligence #178

Dew, I guess you could deduct $5 per share from your valuation model:

http://finance.yahoo.com/news/enanta-regains-full-rights-ns5a-120000172.html
icon url

Double_Bagel

10/20/14 5:07 PM

#652 RE: DewDiligence #178

How does this valuation change based on the royalty and licensing information disclosed in today's PR for both ABT-450 and ABT-493? Thanks.

PS: It hit a life time high of 47.32 after hours on 2 shares :-) However, it is down a little after the licensing news

http://www.nasdaq.com/symbol/enta/after-hours